The recent approval of PARPi treatment in breast cancers with homologous DNA recombination defects and temporal or geographic heterogeneity in PARP overexpression/upregulation highlights the necessity for a non-invasive whole-body in vivo imaging approach which can be used in conjunction with IHC. Here, PARP1 is linked to breast cancer.